Angela Äbelö

694 total citations
26 papers, 541 citations indexed

About

Angela Äbelö is a scholar working on Infectious Diseases, Oncology and Pharmacology. According to data from OpenAlex, Angela Äbelö has authored 26 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 9 papers in Oncology and 8 papers in Pharmacology. Recurrent topics in Angela Äbelö's work include HIV/AIDS drug development and treatment (11 papers), Drug Transport and Resistance Mechanisms (9 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Angela Äbelö is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), Drug Transport and Resistance Mechanisms (9 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Angela Äbelö collaborates with scholars based in Sweden, Rwanda and United Kingdom. Angela Äbelö's co-authors include Lars Weidolf, Tommy B. Andersson, Inger Skånberg, Madeleine Antonsson, Michael Ashton, Mats O. Karlsson, Emile Bienvenu, Johan Gabrielsson, Ulf G. Eriksson and Cornelia von Hagens and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Pharmacology and Experimental Therapeutics and Clinical Pharmacology & Therapeutics.

In The Last Decade

Angela Äbelö

25 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Äbelö Sweden 12 195 123 122 110 108 26 541
Michael Kukulka United States 14 237 1.2× 94 0.8× 256 2.1× 164 1.5× 177 1.6× 28 802
In‐Jin Jang South Korea 14 222 1.1× 105 0.9× 100 0.8× 54 0.5× 70 0.6× 27 660
Masataka Katashima Japan 13 104 0.5× 108 0.9× 104 0.9× 44 0.4× 52 0.5× 46 513
Philip R. Mayer United States 13 195 1.0× 129 1.0× 37 0.3× 50 0.5× 61 0.6× 36 656
Gunilla Englund Sweden 6 124 0.6× 109 0.9× 66 0.5× 30 0.3× 79 0.7× 6 608
Danilo Wegner Germany 12 123 0.6× 120 1.0× 91 0.7× 25 0.2× 48 0.4× 19 582
Chang-Hong Jiang China 9 179 0.9× 122 1.0× 49 0.4× 18 0.2× 39 0.4× 14 478
John Dikran Balian United States 8 383 2.0× 178 1.4× 40 0.3× 26 0.2× 36 0.3× 10 744
Christopher G. Meredith United States 10 188 1.0× 66 0.5× 36 0.3× 134 1.2× 179 1.7× 16 572
I. Yamada Japan 15 93 0.5× 195 1.6× 79 0.6× 20 0.2× 54 0.5× 45 722

Countries citing papers authored by Angela Äbelö

Since Specialization
Citations

This map shows the geographic impact of Angela Äbelö's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Äbelö with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Äbelö more than expected).

Fields of papers citing papers by Angela Äbelö

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Äbelö. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Äbelö. The network helps show where Angela Äbelö may publish in the future.

Co-authorship network of co-authors of Angela Äbelö

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Äbelö. A scholar is included among the top collaborators of Angela Äbelö based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Äbelö. Angela Äbelö is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aicher, Helena, Philippe Müller, Maxim Puchkov, et al.. (2025). Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study. Biomedicine & Pharmacotherapy. 184. 117908–117908. 3 indexed citations
2.
Äbelö, Angela, et al.. (2025). Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects. Biomedicine & Pharmacotherapy. 189. 118329–118329.
3.
4.
Bienvenu, Emile, et al.. (2022). Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. Antimicrobial Agents and Chemotherapy. 66(10). e0227721–e0227721. 1 indexed citations
5.
Bienvenu, Emile, et al.. (2021). Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. Journal of Antimicrobial Chemotherapy. 76(11). 2950–2957. 3 indexed citations
6.
7.
Hoglund, Richard M., et al.. (2016). Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malaria Journal. 15(1). 129–129. 23 indexed citations
8.
Toi, Pham Van, Nguyen Thanh Truong, Thị Dung Nguyễn, et al.. (2016). Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. Malaria Journal. 15(1). 90–90. 16 indexed citations
9.
Blank, Antje, et al.. (2014). Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. European Journal of Clinical Pharmacology. 70(12). 1453–1463. 47 indexed citations
10.
Gennemark, Peter, et al.. (2013). Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. Journal of Pharmacokinetics and Pharmacodynamics. 40(1). 117–128. 11 indexed citations
11.
Bienvenu, Emile, Marelize Swart, Collet Dandara, et al.. (2013). Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations. Current pharmacogenomics and personalized medicine (Online). 11(3). 237–246. 6 indexed citations
12.
Masimirembwa, Collen, et al.. (2013). The Evaluation of CYP2B6 Inhibition by Artemisinin Antimalarials in Recombinant Enzymes and Human Liver Microsomes. Drug Metabolism Letters. 6(4). 247–257. 9 indexed citations
13.
Rekić, Dinko, Daniel Röshammar, Martin Bergstrand, et al.. (2012). External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. The AAPS Journal. 15(2). 308–315. 3 indexed citations
14.
Rekić, Dinko, Daniel Röshammar, Leo Flamholc, et al.. (2011). Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. The AAPS Journal. 13(4). 598–605. 11 indexed citations
15.
16.
Äbelö, Angela, Bjørn Evald Holstein, Ulf G. Eriksson, Johan Gabrielsson, & Mats O. Karlsson. (2002). Gastric Acid Secretion in the Dog: A Mechanism-Based Pharmacodynamic Model for Histamine Stimulation and Irreversible Inhibition by Omeprazole. Journal of Pharmacokinetics and Pharmacodynamics. 29(4). 365–382. 17 indexed citations
17.
Äbelö, Angela, Johan Gabrielsson, Bjørn Evald Holstein, et al.. (2001). Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man. European Journal of Pharmaceutical Sciences. 14(4). 339–346. 8 indexed citations
18.
Äbelö, Angela, Tommy B. Andersson, Ulf Bredberg, Inger Skånberg, & Lars Weidolf. (2000). Stereoselective Metabolism by Human Liver CYP Enzymes of A Substituted Benzimidazole. Drug Metabolism and Disposition. 28(1). 58–64. 16 indexed citations
19.
Äbelö, Angela, Ulf G. Eriksson, Mats O. Karlsson, Håkan Larsson, & Johan Gabrielsson. (2000). A Turnover Model of Irreversible Inhibition of Gastric Acid Secretion by Omeprazole in the Dog. Journal of Pharmacology and Experimental Therapeutics. 295(2). 662–669. 25 indexed citations
20.
Äbelö, Angela, et al.. (2000). Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 28(8). 966–972. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Kukulka Breakdown of academic impact, for papers by In‐Jin Jang Breakdown of academic impact, for papers by Masataka Katashima Breakdown of academic impact, for papers by Philip R. Mayer Breakdown of academic impact, for papers by Gunilla Englund Breakdown of academic impact, for papers by Danilo Wegner Breakdown of academic impact, for papers by Chang-Hong Jiang Breakdown of academic impact, for papers by John Dikran Balian Breakdown of academic impact, for papers by Christopher G. Meredith Breakdown of academic impact, for papers by I. Yamada
Rankless by CCL
2026